Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)

July 14, 2025 6:49 AM EDT Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst commented, “September ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login